Home  »  Technologies   »  Is Vascular Biogenics Ltd. (NASDAQ: VBLT) Still A ...

Is Vascular Biogenics Ltd. (NASDAQ: VBLT) Still A Loss Stock Despite Being Down -87.82% YTD?

During the last session, Vascular Biogenics Ltd. (NASDAQ:VBLT)’s traded shares were 7.4 million, with the beta value of the company hitting 0.67. At the end of the trading day, the stock’s price was $0.24, reflecting an intraday gain of 3.45% or $0.01. The 52-week high for the VBLT share is $2.54, that puts it down -958.33 from that peak though still a striking 12.5% gain since the share price plummeted to a 52-week low of $0.21. The company’s market capitalization is $18.98M, and the average intraday trading volume over the past 10 days was 12.64 million shares, and the average trade volume was 2.17 million shares over the past three months.

Vascular Biogenics Ltd. (VBLT) received a consensus recommendation of a Hold from analysts. That translates to a mean rating of 1.80. VBLT has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.11.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Vascular Biogenics Ltd. (NASDAQ:VBLT) trade information

Vascular Biogenics Ltd. (VBLT) registered a 3.45% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 3.45% in intraday trading to $0.24 this Wednesday, 08/03/22, hitting a weekly high. The stock’s 5-day price performance is -4.38%, and it has moved by -86.21% in 30 days. Based on these gigs, the overall price performance for the year is -88.52%. The short interest in Vascular Biogenics Ltd. (NASDAQ:VBLT) is 0.29 million shares and it means that shorts have 1.92 day(s) to cover.

The consensus price target of analysts on Wall Street is $4.83, which implies an increase of 95.03% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4.00 and $5.50 respectively. As a result, VBLT is trading at a discount of -2191.67% off the target high and -1566.67% off the low.

Vascular Biogenics Ltd. (VBLT) estimates and forecasts

Statistics show that Vascular Biogenics Ltd. has underperformed its competitors in share price, compared to the industry in which it operates. Vascular Biogenics Ltd. (VBLT) shares have gone down -81.95% during the last six months, with a year-to-date growth rate less than the industry average at -13.33% against 1.00. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 8.30% this quarter and then drop -44.40% in the quarter after that. In the rating firms’ projections, revenue will increase 181.30% compared to the previous financial year.

Revenue for the current quarter is expected to be $1.16 million as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to $120k by the end of Sep 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $188k and $199k respectively. In this case, analysts expect current quarter sales to grow by 517.00% and then drop by -39.70% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 6.80%. While earnings are projected to return 18.70% in 2022.

VBLT Dividends

Vascular Biogenics Ltd. is due to release its next quarterly earnings between March 23 and March 28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Vascular Biogenics Ltd. (NASDAQ:VBLT)’s Major holders

Vascular Biogenics Ltd. insiders own 23.95% of total outstanding shares while institutional holders control 20.48%, with the float percentage being 26.93%. Lion Point Capital, LP is the largest shareholder of the company, while 31 institutions own stock in it. As of Mar 30, 2022, the company held over 2.59 million shares (or 5.41% of all shares), a total value of $4.38 million in shares.

The next largest institutional holding, with 1.02 million shares, is of Phoenix Holdings Ltd.’s that is approximately 2.13% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $1.72 million.

Also, the Mutual Funds coming in first place with the largest holdings of Vascular Biogenics Ltd. (VBLT) shares are Delaware Group Equity Fds IV-Delaware Healthcare Fund and Fidelity NASDAQ Composite Index Fund. Data provided on Mar 30, 2022 indicates that Delaware Group Equity Fds IV-Delaware Healthcare Fund owns about 0.2 million shares. This amounts to just over 0.42 percent of the company’s overall shares, with a $0.34 million market value. The same data shows that the other fund manager holds slightly less at 40323.0, or about 0.08% of the stock, which is worth about $74194.0.

Leave a Comment

Your email address will not be published.

On Key

Related Posts